Plaza-Florido, A. et al. The long-lived immune system of centenarians. Nat. Rev. Immunol. https://doi.org/10.1038/s41577-026-01291-5 (2026).
Bellantuono, I. Discover medication that delay many ailments of previous age. Nature 554, 293–295 (2018).
Wilkinson, D. J., Piasecki, M. & Atherton, P. J. The age-related lack of skeletal muscle mass and performance: measurement and physiology of muscle fibre atrophy and muscle fibre loss in people. Ageing Res. Rev. 47, 123–132 (2018).
Anker, S. D., Morley, J. E. & von Haehling, S. Welcome to the ICD-10 code for sarcopenia. J. Cachexia Sarcopenia Muscle 7, 512–514 (2016).
Cruz-Jentoft, A. J. et al. Sarcopenia: revised European consensus on definition and analysis. Age Ageing 48, 16–31 (2019).
Goodpaster, B. H. et al. The lack of skeletal muscle energy, mass, and high quality in older adults: the well being, ageing and physique composition examine. J. Gerontol. A 61, 1059–1064 (2006).
Janssen, I., Heymsfield, S. B. & Ross, R. Low relative skeletal muscle mass (sarcopenia) in older individuals is related to purposeful impairment and bodily incapacity. J. Am. Geriatr. Soc. 50, 889–896 (2002).
Aversa, Z., Zhang, X., Fielding, R. A., Lanza, I. & LeBrasseur, N. Okay. The scientific affect and organic mechanisms of skeletal muscle ageing. Bone 127, 26–36 (2019).
Denison, H. J., Cooper, C., Sayer, A. A. & Robinson, S. M. Prevention and optimum administration of sarcopenia: a overview of mixed train and vitamin interventions to enhance muscle outcomes in older folks. Clin. Interv. Growing older 10, 859–869 (2015).
Dent, E., Woo, J., Scott, D. & Hoogendijk, E. O. Towards the popularity and administration of sarcopenia in routine scientific care. Nat. Growing older 1, 982–990 (2021).
Granic, A., Suetterlin, Okay., Shavlakadze, T., Grounds, M. D. & Sayer, A. A. Hallmarks of ageing in human skeletal muscle and implications for understanding the pathophysiology of sarcopenia in ladies and men. Clin. Sci. 137, 1721–1751 (2023).
Huiskamp, L. F. J., Schaeffers, A. W. M. A., Devriese, L. A. & de Bree, R. The prognostic impact of sarcopenia in stable cancers handled with immunotherapy: a scientific overview and meta-analysis. J. Clin. Med. 15, 2720 (2026).
Sayer, A. A. et al. Sarcopenia. Nat. Rev. Dis. Primers 10, 1–16 (2024).
Goates, S. et al. Financial affect of hospitalizations in US adults with sarcopenia. J. Frailty Growing older 8, 93–99 (2019).
Cohen, S., Nathan, J. A. & Goldberg, A. L. Muscle losing in illness: molecular mechanisms and promising therapies. Nat. Rev. Drug Discov. 14, 58–74 (2015).
Murgia, M. et al. Protein profile of fiber sorts in human skeletal muscle: a single-fiber proteomics examine. Skelet. Muscle 11, 24 (2021).
Katti, P. et al. Mitochondrial community configuration influences sarcomere and myosin filament construction in striated muscle tissue. Nat. Commun. 13, 6058 (2022).
Tamura, Y., Omura, T., Toyoshima, Okay. & Araki, A. Vitamin administration in older adults with diabetes: a overview on the significance of shifting prevention methods from metabolic syndrome to frailty. Vitamins 12, 3367 (2020).
Batsis, J. A., Donini, L. M. & Prado, C. M. Unintended dangers of sarcopenic weight problems throughout weight-loss interventions in older folks. Nat. Med. 32, 776–777 (2026).
Tomonaga, M. Histochemical and ultrastructural adjustments in senile human skeletal muscle. J. Am. Geriatr. Soc. 25, 125–131 (1977).
Schiaffino, S. & Reggiani, C. Myosin isoforms in mammalian skeletal muscle. J. Appl. Physiol. 77, 493–501 (1994).
Larsson, L., Sjödin, B. & Karlsson, J. Histochemical and biochemical adjustments in human skeletal muscle with age in sedentary males, age 22–65 years. Acta Physiol. Scand. 103, 31–39 (1978).
Nilwik, R. et al. The decline in skeletal muscle mass with ageing is especially attributed to a discount in sort II muscle fiber dimension. Exp. Gerontol. 48, 492–498 (2013).
Stožer, A., Vodopivc, P. & Križančić Bombek, L. Pathophysiology of exercise-induced muscle injury and its structural, purposeful, metabolic, and scientific penalties. Physiol. Res. 69, 565–598 (2020).
Kadi, F., Charifi, N., Denis, C. & Lexell, J. Satellite tv for pc cells and myonuclei in younger and aged ladies and men. Muscle Nerve 29, 120–127 (2004).
Chakkalakal, J. V., Jones, Okay. M., Basson, M. A. & Brack, A. S. The aged area of interest disrupts muscle stem cell quiescence. Nature 490, 355–360 (2012).
Brack, A. S. et al. Elevated Wnt signaling throughout ageing alters muscle stem cell destiny and will increase fibrosis. Science 317, 807–810 (2007).
Conboy, I. M., Conboy, M. J., Smythe, G. M. & Rando, T. A. Notch-mediated restoration of regenerative potential to aged muscle. Science 302, 1575–1577 (2003).
Cosgrove, B. D. et al. Rejuvenation of the muscle stem cell inhabitants restores energy to injured aged muscle tissue. Nat. Med. 20, 255–264 (2014).
Wang, Y. X. et al. Multiomic profiling reveals that prostaglandin E2 reverses aged muscle stem cell dysfunction, resulting in elevated regeneration and energy. Cell Stem Cell 32, 1154–1169.e9 (2025).
Porpiglia, E. et al. Elevated CD47 is a trademark of dysfunctional aged muscle stem cells that may be focused to enhance regeneration. Cell Stem Cell 29, 1653–1668 (2022).
Kang, J. et al. Mobile survivorship bias as a mechanistic driver of muscle stem cell ageing. Science 391, 517–521 (2026).
Ancel, S., Stuelsatz, P. & Feige, J. N. Muscle stem cell quiescence: controlling stemness by staying asleep. Developments Cell Biol. 31, 556–568 (2021).
Blau, H. M., Cosgrove, B. D. & Ho, A. T. V. The central position of muscle stem cells in regenerative failure with ageing. Nat. Med. 21, 854–862 (2015).
Perkisas, S., De Cock, A., Verhoeven, V. & Vandewoude, M. Physiological and architectural adjustments within the ageing muscle and their relation to energy and performance in sarcopenia. Eur. Geriatr. Med. 7, 201–206 (2016).
Li, C. et al. Pathogenesis of sarcopenia and the connection with fats mass: descriptive overview. J. Cachexia Sarcopenia Muscle 13, 781–794 (2022).
Fitzgerald, G. et al. MME+ fibro-adipogenic progenitors are the dominant adipogenic inhabitants throughout fatty infiltration in human skeletal muscle. Commun. Biol. 6, 1–21 (2023).
Madaro, L. et al. Denervation-activated STAT3-IL-6 signalling in fibro-adipogenic progenitors promotes myofibres atrophy and fibrosis. Nat. Cell Biol. 20, 917–927 (2018).
Lukjanenko, L. et al. Growing older disrupts muscle stem cell operate by impairing matricellular WISP1 secretion from fibro-adipogenic progenitors. Cell Stem Cell 24, 433–446.e7 (2019).
Uezumi, A., Fukada, S., Yamamoto, N., Takeda, S. & Tsuchida, Okay. Mesenchymal progenitors distinct from satellite tv for pc cells contribute to ectopic fats cell formation in skeletal muscle. Nat. Cell Biol. 12, 143–152 (2010).
Malecova, B. et al. Dynamics of mobile states of fibro-adipogenic progenitors throughout myogenesis and muscular dystrophy. Nat. Commun. 9, 3670 (2018).
Joe, A. W. B. et al. Muscle damage prompts resident fibro/adipogenic progenitors that facilitate myogenesis. Nat. Cell Biol. 12, 153–163 (2010).
Theret, M., Rossi, F. M. V. & Contreras, O. Evolving roles of muscle-resident fibro-adipogenic progenitors in well being, regeneration, neuromuscular issues, and ageing. Entrance. Physiol. 12, 673404 (2021).
Farup, J. et al. Human skeletal muscle CD90+ fibro-adipogenic progenitors are related to muscle degeneration in sort 2 diabetic sufferers. Cell Metab. 33, 2201–2214.e10 (2021).
Fiatarone, M. A. et al. Train coaching and dietary supplementation for bodily frailty in very aged folks. N. Engl. J. Med. 330, 1769–1775 (1994).
Brook, M. S. et al. Synchronous deficits in cumulative muscle protein synthesis and ribosomal biogenesis underlie age-related anabolic resistance to train in people. J. Physiol. 594, 7399–7417 (2016).
Kunz, H. E. & Lanza, I. R. Age-associated irritation and implications for skeletal muscle responses to train. Exp. Gerontol. 177, 112177 (2023).
Tylutka, A., Walas, Ł & Zembron-Lacny, A. Degree of IL-6, TNF, and IL-1β and age-related ailments: a scientific overview and meta-analysis. Entrance. Immunol. 15, 1330386 (2024).
Cai, D. et al. IKKβ/NF-κB activation causes extreme muscle losing in mice. Cell 119, 285–298 (2004).
Bakkar, N. et al. IKK/NF-κB regulates skeletal myogenesis by way of a signaling change to inhibit differentiation and promote mitochondrial biogenesis. J. Cell Biol. 180, 787–802 (2008).
Mittal, A. et al. The TWEAK-Fn14 system is a important regulator of denervation-induced skeletal muscle atrophy in mice. J. Cell Biol. 188, 833–849 (2010).
Mourkioti, F. et al. Focused ablation of IKK2 improves skeletal muscle energy, maintains mass, and promotes regeneration. J. Clin. Make investments. 116, 2945–2954 (2006).
Ji, Y. et al. Irritation: roles in skeletal muscle atrophy. Antioxidants 11, 1686 (2022).
Widjaja, A. A. et al. Inhibition of IL-11 signalling extends mammalian healthspan and lifespan. Nature 632, 157–165 (2024).
Brorson, J. et al. Complementing muscle regeneration-fibro-adipogenic progenitor and macrophage-mediated restore of aged human skeletal muscle. Nat. Commun. 16, 5233 (2025).
Groen, B. B. L. et al. Skeletal muscle capillary density and microvascular operate are compromised with ageing and sort 2 diabetes. J. Appl. Physiol. 116, 998–1005 (2014).
Zhang, X. et al. Characterization of mobile senescence in ageing skeletal muscle. Nat. Growing older 2, 601–615 (2022).
Kedlian, V. R. et al. Human skeletal muscle ageing atlas. Nat. Growing older 4, 727–744 (2024).
Jeon, Y. Okay. et al. Vascular dysfunction as a possible offender of sarcopenia. Exp. Gerontol. 145, 111220 (2021).
Lin, H. et al. Decoding the transcriptome of denervated muscle at single-nucleus decision. J. Cachexia Sarcopenia Muscle 13, 2102–2117 (2022).
Tamaki, T., Hirata, M. & Uchiyama, Y. Qualitative alteration of peripheral motor system begins previous to look of typical sarcopenia syndrome in middle-aged rats. Entrance. Growing older Neurosci. 6, 296 (2014).
Pannérec, A. et al. A sturdy neuromuscular system protects rat and human skeletal muscle from sarcopenia. Growing older 8, 712–728 (2016).
Larsson, L. et al. Sarcopenia: aging-related lack of muscle mass and performance. Physiol. Rev. 99, 427–511 (2019).
Kelly, N. A. et al. Quantification and characterization of grouped sort I myofibers in human ageing. Muscle Nerve 57, E52–E59 (2018).
Hunter, S. Okay., Pereira, H. M. & Keenan, Okay. G. The ageing neuromuscular system and motor efficiency. J. Appl. Physiol. 121, 982–995 (2016).
Palla, A. R. et al. Inhibition of prostaglandin-degrading enzyme 15-PGDH rejuvenates aged muscle mass and energy. Science 371, eabc8059 (2021).
Bakooshli, M. A. et al. Regeneration of neuromuscular synapses after acute and continual denervation by inhibiting the gerozyme 15-prostaglandin dehydrogenase. Sci. Transl. Med. 15, eadg1485 (2023).
Bodine, S. C. et al. Akt/mTOR pathway is an important regulator of skeletal muscle hypertrophy and might stop muscle atrophy in vivo. Nat. Cell Biol. 3, 1014–1019 (2001).
Rommel, C. et al. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)Okay/Akt/mTOR and PI(3)Okay/Akt/GSK3 pathways. Nat. Cell Biol. 3, 1009–1013 (2001).
Hargreaves, M. & Spriet, L. L. Skeletal muscle vitality metabolism throughout train. Nat. Metab. 2, 817–828 (2020).
Baskin, Okay. Okay., Winders, B. R. & Olson, E. N. Muscle as a ‘mediator’ of systemic metabolism. Cell Metab. 21, 237–248 (2015).
Takenaka, N., Araki, N. & Satoh, T. Involvement of the protein kinase Akt2 in insulin-stimulated Rac1 activation resulting in glucose uptake in mouse skeletal muscle. PLoS ONE 14, e0212219 (2019).
Saxton, R. A. & Sabatini, D. M. mTOR signaling in development, metabolism, and illness. Cell 168, 960–976 (2017).
Schiaffino, S., Dyar, Okay. A., Ciciliot, S., Blaauw, B. & Sandri, M. Mechanisms regulating skeletal muscle development and atrophy. FEBS J. 280, 4294–4314 (2013).
Lai, Okay.-M. V. et al. Conditional activation of Akt in grownup skeletal muscle induces fast hypertrophy. Mol. Cell Biol. 24, 9295–9304 (2004).
Kurth-Kraczek, E. J., Hirshman, M. F., Goodyear, L. J. & Winder, W. W. 5′ AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle. Diabetes 48, 1667–1671 (1999).
Sanchez, A. M. J. et al. AMPK promotes skeletal muscle autophagy via activation of forkhead FoxO3a and interplay with Ulk1. J. Cell Biochem. 113, 695–710 (2012).
Egan, D. F. et al. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects vitality sensing to mitophagy. Science 331, 456–461 (2011).
Jäger, S., Handschin, C., St-Pierre, J. & Spiegelman, B. M. AMP-activated protein kinase (AMPK) motion in skeletal muscle by way of direct phosphorylation of PGC-1α. Proc. Natl Acad. Sci. USA 104, 12017–12022 (2007).
Sandri, M. et al. Signalling pathways regulating muscle mass in ageing skeletal muscle: the position of the IGF1-Akt-mTOR-FoxO pathway. Biogerontology 14, 303–323 (2013).
Zuo, X. et al. Multi-omic profiling of sarcopenia identifies disrupted branched-chain amino acid catabolism as a causal mechanism and therapeutic goal. Nat. Growing older 5, 419–436 (2025).
Quy, P. N., Kuma, A., Pierre, P. & Mizushima, N. Proteasome-dependent activation of mammalian goal of rapamycin advanced 1 (mTORC1) is crucial for autophagy suppression and muscle transforming following denervation. J. Biol. Chem. 288, 13639 (2013).
Castets, P. et al. Sustained activation of mTORC1 in skeletal muscle inhibits constitutive and starvation-induced autophagy and causes a extreme, late-onset myopathy. Cell Metab. 17, 731–744 (2013).
Zhou, J. et al. Modifications in macroautophagy, chaperone-mediated autophagy, and mitochondrial metabolism in murine skeletal and cardiac muscle throughout ageing. Growing older 9, 583–599 (2017).
Baehr, L. M. et al. Age-related deficits in skeletal muscle restoration following disuse are related to neuromuscular junction instability and ER stress, not impaired protein synthesis. Growing older 8, 127–146 (2016).
Tezze, C. et al. Age-associated lack of OPA1 in muscle impacts muscle mass, metabolic homeostasis, systemic irritation, and epithelial senescence. Cell Metab. 25, 1374–1389.e6 (2017).
Sebastián, D. et al. Mfn2 deficiency hyperlinks age-related sarcopenia and impaired autophagy to activation of an adaptive mitophagy pathway. EMBO J. 35, 1677–1693 (2016).
Gouspillou, G. et al. Elevated sensitivity to mitochondrial permeability transition and myonuclear translocation of endonuclease G in atrophied muscle of bodily lively older people. FASEB J. 28, 1621–1633 (2014).
Drummond, M. J. et al. Downregulation of E3 ubiquitin ligases and mitophagy-related genes in skeletal muscle of bodily inactive, frail older girls: a cross-sectional comparability. J. Gerontol. A 69, 1040–1048 (2014).
Palikaras, Okay., Lionaki, E. & Tavernarakis, N. Mechanisms of mitophagy in mobile homeostasis, physiology and pathology. Nat. Cell Biol. 20, 1013–1022 (2018).
Andersson, D. C. et al. Ryanodine receptor oxidation causes intracellular calcium leak and muscle weak spot in ageing. Cell Metab. 14, 196–207 (2011).
Qaisar, R. et al. Restoration of sarcoplasmic reticulum Ca2+ ATPase (SERCA) exercise prevents age-related muscle atrophy and weak spot in mice. Int. J. Mol. Sci. 22, 37 (2020).
Yakes, F. M. & Van Houten, B. Mitochondrial DNA injury is extra intensive and persists longer than nuclear DNA injury in human cells following oxidative stress. Proc. Natl Acad. Sci. USA 94, 514–519 (1997).
Bua, E. et al. Mitochondrial DNA-deletion mutations accumulate intracellularly to detrimental ranges in aged human skeletal muscle fibers. Am. J. Hum. Genet. 79, 469–480 (2006).
Herbst, A. et al. Mitochondrial DNA deletion mutations enhance exponentially with age in human skeletal muscle. Growing older Clin. Exp. Res. 33, 1811–1820 (2021).
Herbst, A. et al. Latent mitochondrial DNA deletion mutations drive muscle fiber loss at previous age. Growing older Cell 15, 1132–1139 (2016).
Fan, Z., Yang, J., Guo, Y., Liu, Y. & Zhong, X. Altered ranges of circulating mitochondrial DNA in aged folks with sarcopenia: affiliation with mitochondrial impairment. Exp. Gerontol. 163, 111802 (2022).
Quick, Okay. R. et al. Decline in skeletal muscle mitochondrial operate with ageing in people. Proc. Natl Acad. Sci. USA 102, 5618–5623 (2005).
Bodine, S. C. et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294, 1704–1708 (2001).
Gomes, M. D., Lecker, S. H., Jagoe, R. T., Navon, A. & Goldberg, A. L. Atrogin-1, a muscle-specific F-box protein extremely expressed throughout muscle atrophy. Proc. Natl Acad. Sci. USA 98, 14440–14445 (2001).
Soendenbroe, C., Andersen, J. L. & Mackey, A. L. Muscle-nerve communication and the molecular evaluation of human skeletal muscle denervation with ageing. Am. J. Physiol. Cell Physiol. 321, C317–C329 (2021).
Dos Santos, M. et al. Opposing gene regulatory packages governing myofiber improvement and maturation revealed at single nucleus decision. Nat. Commun. 14, 4333 (2023).
Puigserver, P. et al. A chilly-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92, 829–839 (1998).
Wu, Z. et al. Mechanisms controlling mitochondrial biogenesis and respiration via the thermogenic coactivator PGC-1. Cell 98, 115–124 (1999).
Coen, P. M. et al. Skeletal muscle mitochondrial energetics are related to maximal cardio capability and strolling velocity in older adults. J. Gerontol. A 68, 447–455 (2013).
Migliavacca, E. et al. Mitochondrial oxidative capability and NAD+ biosynthesis are diminished in human sarcopenia throughout ethnicities. Nat. Commun. 10, 5808 (2019).
Lin, J. et al. Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 418, 797–801 (2002).
Sandri, M. et al. PGC-1α protects skeletal muscle from atrophy by suppressing FoxO3 motion and atrophy-specific gene transcription. Proc. Natl Acad. Sci. USA 103, 16260–16265 (2006).
Handschin, C. et al. PGC-1α regulates the neuromuscular junction program and ameliorates Duchenne muscular dystrophy. Genes Dev. 21, 770–783 (2007).
Bodine, S. C. & Baehr, L. M. Skeletal muscle atrophy and the E3 ubiquitin ligases MuRF1 and MAFbx/atrogin-1. Am. J. Physiol. Endocrinol. Metab. 307, E469–E484 (2014).
Milan, G. et al. Regulation of autophagy and the ubiquitin–proteasome system by the FoxO transcriptional community throughout muscle atrophy. Nat. Commun. 6, 6670 (2015).
Sartori, R. et al. Perturbed BMP signaling and denervation promote muscle losing in most cancers cachexia. Sci. Transl. Med. 13, eaay9592 (2021).
Sandri, M. et al. Foxo transcription components induce the atrophy-related ubiquitin ligase atrogin-1 and trigger skeletal muscle atrophy. Cell 117, 399–412 (2004).
Sartori, R. et al. Smad2 and three transcription components management muscle mass in maturity. Am. J. Physiol. Cell Physiol. 296, C1248–C1257 (2009).
Stitt, T. N. et al. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription components. Mol. Cell 14, 395–403 (2004).
Altun, M. et al. Muscle losing in aged, sarcopenic rats is related to enhanced exercise of the ubiquitin proteasome pathway. J. Biol. Chem. 285, 39597–39608 (2010).
Segalés, J. et al. Sestrin prevents atrophy of disused and ageing muscle tissue by integrating anabolic and catabolic indicators. Nat. Commun. 11, 189 (2020).
Shavlakadze, T. et al. Age-related gene expression signatures from limb skeletal muscle tissue and the diaphragm in mice and rats reveal frequent and species-specific adjustments. Skelet. Muscle 13, 11 (2023).
Stefanetti, R. J. et al. Ageing has no impact on the regulation of the ubiquitin proteasome-related genes and proteins following resistance train. Entrance. Physiol. 5, 30 (2014).
McPherron, A. C. & Lee, S. J. Double muscling in cattle resulting from mutations within the myostatin gene. Proc. Natl Acad. Sci. USA 94, 12457–12461 (1997).
Trendelenburg, A. U. et al. Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube dimension. Am. J. Physiol. Cell Physiol. 296, C1258–C1270 (2009).
McPherron, A. C., Lawler, A. M. & Lee, S. J. Regulation of skeletal muscle mass in mice by a brand new TGF-β superfamily member. Nature 387, 83–90 (1997).
Amthor, H. et al. Lack of myostatin ends in extreme muscle development however impaired pressure technology. Proc. Natl Acad. Sci. USA 104, 1835–1840 (2007).
Zhang, C. et al. Inhibition of myostatin protects in opposition to diet-induced weight problems by enhancing fatty acid oxidation and selling a brown adipose phenotype in mice. Diabetologia 55, 183–193 (2012).
Yarasheski, Okay. E., Bhasin, S., Sinha-Hikim, I., Pak-Loduca, J. & Gonzalez-Cadavid, N. F. Serum myostatin-immunoreactive protein is elevated in 60–92 yr previous ladies and men with muscle losing. J. Nutr. Well being Growing older 6, 343–348 (2002).
Ratkevicius, A. et al. Serum concentrations of myostatin and myostatin-interacting proteins don’t differ between younger and sarcopenic aged males. J. Gerontol. A 66, 620–626 (2011).
Wolfman, N. M. et al. Activation of latent myostatin by the BMP-1/tolloid household of metalloproteinases. Proc. Natl Acad. Sci. USA 100, 15842–15846 (2003).
Winbanks, C. E. et al. Follistatin-mediated skeletal muscle hypertrophy is regulated by Smad3 and mTOR independently of myostatin. J. Cell Biol. 197, 997–1008 (2012).
Núñez-Robainas, A., Guitart, M., López-Postigo, A., Sancho-Muñoz, A. & Barreiro, E. Myostatin/Smad2/Smad3 pathway outline a differential scientific phenotype in COPD-associated sarcopenia. ERJ Open Res. 11, 00772-2024 (2025).
Biagetti, B. & Puig-Domingo, M. Age-related hormones adjustments and its affect on well being standing and lifespan. Growing older Dis. 14, 605–620 (2023).
Harman, S. M. et al. Longitudinal results of ageing on serum complete and free testosterone ranges in wholesome males. Baltimore Longitudinal Examine of Growing older. J. Clin. Endocrinol. Metab. 86, 724–731 (2001).
Sipilä, S. et al. Intercourse hormones and skeletal muscle weak spot. Biogerontology 14, 231–245 (2013).
Bian, A. et al. Affiliation between sarcopenia and ranges of development hormone and insulin-like development factor-1 within the aged. BMC Musculoskelet. Disord. 21, 214 (2020).
Ricciotti, E. & FitzGerald, G. A. Prostaglandins and irritation. Arterioscler. Thromb. Vasc. Biol. 31, 986–1000 (2011).
Huang, H. et al. The sustained PGE2 launch matrix improves neovascularization and skeletal muscle regeneration in a hindlimb ischemia mannequin. J. Nanobiotechnol. 20, 95 (2022).
Park, J. Y., Pillinger, M. H. & Abramson, S. B. Prostaglandin E2 synthesis and secretion: the position of PGE2 synthases. Clin. Immunol. 119, 229–240 (2006).
Ho, A. T. V. et al. Prostaglandin E2 is crucial for efficacious skeletal muscle stem-cell operate, augmenting regeneration and energy. Proc. Natl Acad. Sci. USA. 114, 6675–6684 (2017).
Guerci, A. et al. Srf-dependent paracrine indicators produced by myofibers management satellite tv for pc cell-mediated skeletal muscle hypertrophy. Cell Metab. 15, 25–37 (2012).
Bernabei, R. et al. Multicomponent intervention to stop mobility incapacity in frail older adults: randomised managed trial (SPRINTT challenge). BMJ 377, e068788 (2022).
Pahor, M. et al. Impact of structured bodily exercise on prevention of main mobility incapacity in older adults: the life examine randomized scientific trial. JAMA 311, 2387–2396 (2014).
Cartee, G. D., Hepple, R. T., Bamman, M. M. & Zierath, J. R. Train promotes wholesome ageing of skeletal muscle. Cell Metab. 23, 1034–1047 (2016).
McKendry, J. et al. Dietary dietary supplements to help resistance train in countering the sarcopenia of ageing. Vitamins 12, 2057 (2020).
Amar, D. et al. Temporal dynamics of the multi-omic response to endurance train coaching. Nature 629, 174–183 (2024).
Wesselink, E., Koekkoek, W. A. C., Grefte, S., Witkamp, R. F. & van Zanten, A. R. H. Feeding mitochondria: potential position of dietary elements to enhance important sickness convalescence. Clin. Nutr. 38, 982–995 (2019).
D’Amico, D. et al. Impression of the pure compound urolithin A on well being, illness, and ageing. Developments Mol. Med. 27, 687–699 (2021).
Lopez-Otin, C., Blasco, M. A., Partridge, L., Serrano, M. & Kroemer, G. The hallmarks of ageing. Cell 153, 1194–1217 (2013).
Faitg, J., D’Amico, D., Rinsch, C. & Singh, A. Mitophagy activation by urolithin A to focus on muscle ageing. Calcif. Tissue Int. 114, 53–59 (2024).
Luan, P. et al. Urolithin A improves muscle operate by inducing mitophagy in muscular dystrophy. Sci. Transl. Med. 13, eabb0319 (2021).
Ryu, D. et al. Urolithin A induces mitophagy and prolongs lifespan in C. elegans and will increase muscle operate in rodents. Nat. Med. 22, 879–888 (2016).
Ghosh, N. et al. Urolithin A augments angiogenic pathways in skeletal muscle by bolstering NAD+ and SIRT1. Sci. Rep. 10, 20184 (2020).
D’Amico, D. et al. Urolithin A improves mitochondrial well being, reduces cartilage degeneration, and alleviates ache in osteoarthritis. Growing older Cell 21, e13662 (2022).
Fu, X. et al. Urolithin A targets the PI3K/Akt/NF-κB pathways and prevents IL-1β-induced inflammatory response in human osteoarthritis: in vitro and in vivo research. Meals Funct. 10, 6135–6146 (2019).
Andreux, P. A. et al. Mitochondrial operate is impaired within the skeletal muscle of pre-frail aged. Sci. Rep. 8, 8548 (2018).
Andreux, P. A. et al. The mitophagy activator urolithin A is secure and induces a molecular signature of improved mitochondrial and mobile well being in people. Nat. Metab. 1, 595–603 (2019).
Denk, D. et al. Impact of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial. Nat. Growing older 5, 2309–2322 (2025).
Liu, S. et al. Impact of urolithin A supplementation on muscle endurance and mitochondrial well being in older adults: a randomized scientific trial. JAMA Netw. Open 5, e2144279 (2022).
Singh, A. et al. Urolithin A improves muscle energy, train efficiency, and biomarkers of mitochondrial well being in a randomized trial in middle-aged adults. Cell Rep. Med. 3, 100633 (2022).
Christian W. & Warburg, O. Pyridine, the hydrogen transfusing element of fermentative enzymes. Helv. Chim. Acta 19, 79–88 (1936).
Cantó, C. et al. Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and train in skeletal muscle. Cell Metab. 11, 213–219 (2010).
Chen, D. et al. Tissue-specific regulation of SIRT1 by calorie restriction. Genes Dev. 22, 1753–1757 (2008).
Cerletti, M., Jang, Y. C., Finley, L. W. S., Haigis, M. C. & Wagers, A. J. Quick-term calorie restriction enhances skeletal muscle stem cell operate. Cell Stem Cell 10, 515–519 (2012).
Fulco, M. et al. Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 via AMPK-mediated regulation of Nampt. Dev. Cell 14, 661–673 (2008).
Cantó, C. et al. AMPK regulates vitality expenditure by modulating NAD+ metabolism and SIRT1 exercise. Nature 458, 1056–1060 (2009).
Costford, S. R. et al. Skeletal muscle NAMPT is induced by train in people. Am. J. Physiol. Endocrinol. Metab. 298, E117–E126 (2010).
Seyedsadjadi, N. et al. Excessive protein consumption is related to low plasma NAD+ ranges in a wholesome human cohort. PLoS ONE 13, e0201968 (2018).
Cantó, C. et al. The NAD+ precursor nicotinamide riboside enhances oxidative metabolism and protects in opposition to high-fat diet-induced weight problems. Cell Metab. 15, 838–847 (2012).
Gomes, A. P. et al. Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication throughout ageing. Cell 155, 1624–1638 (2013).
Katsyuba, E., Romani, M., Hofer, D. & Auwerx, J. NAD+ homeostasis in well being and illness. Nat. Metab. 2, 9–31 (2020).
Janssens, G. E. et al. Wholesome ageing and muscle operate are positively related to NAD+ abundance in people. Nat. Growing older 2, 254–263 (2022).
Yoshino, J., Mills, Okay. F., Yoon, M. J. & Imai, S. Nicotinamide mononucleotide, a key NAD+ intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 14, 528–536 (2011).
de Guia, R. M. et al. Cardio and resistance train coaching reverses age-dependent decline in NAD+ salvage capability in human skeletal muscle. Physiol. Rep. 7, e14139 (2019).
Zhang, H. et al. NAD+ repletion improves mitochondrial and stem cell operate and enhances life span in mice. Science https://doi.org/10.1126/science.aaf2693 (2016).
Camacho-Pereira, J. et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction via an SIRT3-dependent mechanism. Cell Metab. 23, 1127–1139 (2016).
Tarragó, M. G. et al. A potent and particular CD38 inhibitor ameliorates age-related metabolic dysfunction by reversing tissue NAD+ decline. Cell Metab. 27, 1081–1095.e10 (2018).
Das, A. et al. Impairment of an endothelial NAD+–H2S signaling community is a reversible reason behind vascular ageing. Cell 173, 74–89.e20 (2018).
Yoshino, J., Baur, J. A. & Imai, S.-I. NAD+ intermediates: the biology and therapeutic potential of NMN and NR. Cell Metab. 27, 513–528 (2018).
Christen, S. et al. The differential affect of three completely different NAD+ boosters on circulatory NAD and microbial metabolism in people. Nat. Metab. 8, 62–73 (2026).
Romani, M. et al. NAD+ boosting reduces age-associated amyloidosis and restores mitochondrial homeostasis in muscle. Cell Rep. 34, 108660 (2021).
Martens, C. R. et al. Persistent nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in wholesome middle-aged and older adults. Nat. Commun. 9, 1286 (2018).
Dolopikou, C. F. et al. Acute nicotinamide riboside supplementation improves redox homeostasis and train efficiency in previous people: a double-blind cross-over examine. Eur. J. Nutr. 59, 505–515 (2020).
Jensen, J. B. et al. A randomized placebo-controlled trial of nicotinamide riboside and pterostilbene supplementation in experimental muscle damage in aged people. JCI Perception https://doi.org/10.1172/jci.insight.158314 (2022).
Ashihara, H. et al. Trigonelline and associated nicotinic acid metabolites: prevalence, biosynthesis, taxonomic issues, and their roles in planta and in human well being. Phytochem. Rev. 14, 765–798 (2015).
Barton, W. et al. The microbiome {of professional} athletes differs from that of extra sedentary topics in composition and significantly on the purposeful metabolic degree. Intestine 67, 625–633 (2018).
Membrez, M. et al. Trigonelline is an NAD+ precursor that improves muscle operate throughout ageing and is diminished in human sarcopenia. Nat. Metab. 6, 433–447 (2024).
Chubanava, S. et al. NAD depletion in skeletal muscle doesn’t compromise muscle operate or speed up ageing. Cell Metab. 37, 1460–1481.e17 (2025).
Frederick, D. W. et al. Lack of NAD homeostasis results in progressive and reversible degeneration of skeletal muscle. Cell Metab. 24, 269–282 (2016).
Vinten, Okay. T. et al. NAD+ precursor supplementation in human ageing: scientific proof and challenges. Nat. Metab. 7, 1974–1990 (2025).
Clewell, A. E. et al. A complete toxicological security evaluation of an extract of Olea europaea L. leaves (BonoliveTM). Int. J. Toxicol. 35, 208–221 (2016).
Barbaro, B. et al. Results of the olive-derived polyphenol oleuropein on human well being. Int. J. Mol. Sci. 15, 18508–18524 (2014).
Gherardi, G. et al. Mitochondrial calcium uptake declines throughout ageing and is immediately activated by oleuropein to spice up vitality metabolism and skeletal muscle efficiency. Cell Metab. 37, 477–495.e11 (2024).
Zampieri, S. et al. Bodily train in ageing human skeletal muscle will increase mitochondrial calcium uniporter expression ranges and impacts mitochondria dynamics. Physiol. Rep. 4, e13005 (2016).
Pietrangelo, L. et al. Age-dependent uncoupling of mitochondria from Ca2+ launch models in skeletal muscle. Oncotarget 6, 35358–35371 (2015).
Garbincius, J. F. & Elrod, J. W. Mitochondrial calcium change in physiology and illness. Physiol. Rev. 102, 893–992 (2022).
Zhang, Y. et al. Inhibition of the prostaglandin-degrading enzyme 15-PGDH potentiates tissue regeneration. Science 348, aaa2340 (2015).
Singh, A., Faccenda, D. & Campanella, M. Pharmacological advances in mitochondrial remedy. EBioMedicine 65, 103244 (2021).
Horcajada, M.-N. et al. An oleuropein-based dietary complement might enhance joint purposeful capability in older folks with excessive knee joint ache: findings from a multicentre-RCT and submit hoc evaluation. Ther. Adv. Musculoskelet. Dis. 14, 1759720X211070205 (2022).
Chavez, J. D. et al. Mitochondrial protein interplay panorama of SS-31. Proc. Natl Acad. Sci. USA 117, 15363–15373 (2020).
Karaa, A. et al. Randomized dose-escalation trial of elamipretide in adults with major mitochondrial myopathy. Neurology 90, e1212–e1221 (2018).
Kumagai, H. et al. MOTS-c modulates skeletal muscle operate by immediately binding and activating CK2. iScience 27, 111212 (2024).
Reynolds, J. C. et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent bodily decline and muscle homeostasis. Nat. Commun. 12, 470 (2021).
Kim, H., Kim, J., Lee, C. & Kim, S. Vitamin and train for sarcopenia remedy. Osteoporos. Sarcopenia 11, 54–64 (2025).
Shen, Y. et al. Train for sarcopenia in older folks: a scientific overview and community meta-analysis. J. Cachexia Sarcopenia Muscle 14, 1199–1211 (2023).
Kuzuya, M. et al. Dietary administration tips for sarcopenia and frailty 2025. Geriatrics Gerontol. Int. 25, 5–53 (2025).
Robinson, S., Granic, A., Cruz-Jentoft, A. J. & Sayer, A. A. The position of vitamin within the prevention of sarcopenia. Am. J. Clin. Nutr. 118, 852–864 (2023).
Ham, D. J. et al. The neuromuscular junction is a focus of mTORC1 signaling in sarcopenia. Nat. Commun. 11, 4510 (2020).
Joseph, G. A. et al. Partial inhibition of mTORC1 in aged rats counteracts the decline in muscle mass and reverses molecular signaling related to sarcopenia. Mol. Cell Biol. 39, e00141-19 (2019).
Markofski, M. M. et al. Impact of age on basal muscle protein synthesis and mTORC1 signaling in a big cohort of younger and older women and men. Exp. Gerontol. 65, 1–7 (2015).
Tang, H. et al. mTORC1 promotes denervation-induced muscle atrophy via a mechanism involving the activation of foxO and E3 ubiquitin ligases. Sci. Sign. 7, ra18 (2014).
White, Z., White, R. B., McMahon, C., Grounds, M. D. & Shavlakadze, T. Excessive mTORC1 signaling is maintained, whereas protein degradation pathways are perturbed in previous murine skeletal muscle tissue within the fasted state. Int. J. Biochem. Cell Biol. 78, 10–21 (2016).
Bielas, J. et al. Long run rapamycin remedy improves mitochondrial DNA high quality in ageing mice. Exp. Gerontol. 106, 125–131 (2018).
Ham, A. S. et al. mTORC1 signalling is just not important for the upkeep of muscle mass and performance in grownup sedentary mice. J. Cachexia Sarcopenia Muscle 11, 259–273 (2020).
Mannick, J. B. & Lamming, D. W. Concentrating on the biology of ageing with mTOR inhibitors. Nat. Growing older 3, 642–660 (2023).
Mannick, J. B. et al. TORC1 inhibition enhances immune operate and reduces infections within the aged. Sci. Transl. Med. 10, eaaq1564 (2018).
Sartori, R., Romanello, V. & Sandri, M. Mechanisms of muscle atrophy and hypertrophy: implications in well being and illness. Nat. Commun. 12, 330 (2021).
Saitoh, M. et al. Myostatin inhibitors as pharmacological remedy for muscle losing and muscular dystrophy. JCSM Clin. Rep. 2, 1–10 (2017).
Latres, E. et al. Myostatin blockade with a completely human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in younger and aged mice. Skelet. Muscle 5, 34 (2015).
Camporez, J.-P. G. et al. Anti-myostatin antibody will increase muscle mass and energy and improves insulin sensitivity in previous mice. Proc. Natl Acad. Sci. USA 113, 2212–2217 (2016).
Lach-Trifilieff, E. et al. An antibody blocking activin sort II receptors induces sturdy skeletal muscle hypertrophy and protects from atrophy. Mol. Cell Biol. 34, 606–618 (2014).
Becker, C. et al. Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, section 2 trial. Lancet Diabetes Endocrinol. 3, 948–957 (2015).
Rooks, D. et al. Bimagrumab vs optimized normal of take care of remedy of sarcopenia in community-dwelling older adults: a randomized scientific trial. JAMA Netw. Open 3, e2020836 (2020).
Rooks, D. et al. Remedy of sarcopenia with bimagrumab: outcomes from a section II, randomized, managed, proof-of-concept examine. J. Am. Geriatr. Soc. 65, 1988–1995 (2017).
Barrett, D. et al. A randomized section 1 security, pharmacokinetic and pharmacodynamic examine of the novel myostatin inhibitor apitegromab (SRK-015): a possible remedy for spinal muscular atrophy. Adv. Ther. 38, 3203–3222 (2021).
Costa, E. M., Blau, H. M. & Feldman, D. 1,25-Dihydroxyvitamin D3 receptors and hormonal responses in cloned human skeletal muscle cells. Endocrinology 119, 2214–2220 (1986).
North, T. E. et al. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature 447, 1007–1011 (2007).
Rodemann, H. P., Waxman, L. & Goldberg, A. L. The stimulation of protein degradation in muscle by Ca2+ is mediated by prostaglandin E2 and doesn’t require the calcium-activated protease. J. Biol. Chem. 257, 8716–8723 (1982).
Rodemann, H. P. & Goldberg, A. L. Arachidonic acid, prostaglandin E2 and F2 alpha affect charges of protein turnover in skeletal and cardiac muscle. J. Biol. Chem. 257, 1632–1638 (1982).
Brose, S. A., Thuen, B. T. & Golovko, M. Y. LC/MS/MS technique for evaluation of E2 collection prostaglandins and isoprostanes. J. Lipid Res. 52, 850–859 (2011).
Yang, T. & Du, Y. Distinct roles of central and peripheral prostaglandin E2 and EP subtypes in blood stress regulation. Am. J. Hypertens. 25, 1042–1049 (2012).
Epirium Bio. Epirium Bio proclaims constructive section 1 scientific trial outcomes evaluating MF-300 in wholesome volunteers. https://epirium.com/wp-content/uploads/2025/09/09-24-25-Epirium-Bio-Announces-Positive-Phase-1-Clinical-Trial-Results-Evaluating-MF-300-in-Healthy-Volunteers.pdf (2025).
Webster, M., Martin, J., Fahr, B. & Khairallah, R. MF-300 (15-PGDH enzyme inhibitor) reverses age-related muscle weak spot in mice by restoring muscle high quality. Innov. Growing older 8, 1145 (2024).
Webster, M. et al. P03 administration of MF-300, an orally bioavailable small molecule inhibitor of 15-PGDH, demonstrates improved muscle pressure in preclinical fashions of neuromuscular dysfunction and illness. Neuromuscul. Disord. 33, S162–S163 (2023).
MacConell, L., Shah, A., Mould, D., Lavu, S. & Webster, M. Part 1 analysis of MF-300: an investigational first-in-class oral candidate for sarcopenia. Innov. Growing older 9, igaf122.3994 (2025).
Smith, J. N. P. et al. Therapeutic concentrating on of 15-PGDH in murine pulmonary fibrosis. Sci. Rep. 10, 11657 (2020).
Kim, B. W. et al. 15-Hydroxyprostaglandin dehydrogenase inhibitor prevents contrast-induced acute kidney damage. Ren. Fail. 43, 168–179 (2021).
Ho, W. J. et al. 15-PGDH regulates hematopoietic and gastrointestinal health throughout ageing. PLoS ONE 17, e0268787 (2022).
Koh, Y. et al. Inhibiting 15-PGDH blocks blood-brain barrier deterioration and protects mice from Alzheimer’s illness and traumatic mind damage. Proc. Natl Acad. Sci. USA 122, e2417224122 (2025).
Singla, M. et al. Inhibition of 15-hydroxy prostaglandin dehydrogenase promotes cartilage regeneration. Science 391, 1053–1062 (2025).
Maggio, M., Ble, A., Ceda, G. P. & Metter, E. J. Decline in insulin-like development factor-I ranges throughout grownup life span in two giant inhabitants research. J. Gerontol. A 61, 182–183 (2006).
Sattler, F. R. Development hormone within the ageing male. Finest Pract. Res. Clin. Endocrinol. Metab. 27, 541–555 (2013).
Rolland, Y., Dray, C., Vellas, B. & Barreto, P. D. S. Present and investigational drugs for the remedy of sarcopenia. Metab. Clin. Exp. 149, 155597 (2023).
Rubeck, Okay. Z., Bertelsen, S., Vestergaard, P. & Jørgensen, J. O. L. Impression of GH substitution on train capability and muscle energy in GH-deficient adults: a meta-analysis of blinded, placebo-controlled trials. Clin. Endocrinol. 71, 860–866 (2009).
Widdowson, W. M. & Gibney, J. The impact of development hormone (GH) substitute on muscle energy in sufferers with GH-deficiency: a meta-analysis. Clin. Endocrinol. 72, 787–792 (2010).
Kiel, D. P. et al. Lack of an affiliation between insulin-like development factor-I and physique composition, muscle energy, bodily efficiency or self-reported mobility amongst older individuals with purposeful limitations. J. Am. Geriatr. Soc. 46, 822–828 (1998).
Correa, C., Bieger, P., Perry, I. S. & Souza, G. C. Testosterone supplementation on sarcopenia elements in continual sufferers: a scientific overview and meta-analysis. Curr. Pharm. Des. 28, 586–594 (2022).
Parahiba, S. M. et al. Impact of testosterone supplementation on sarcopenic elements in middle-aged and aged males: a scientific overview and meta-analysis. Exp. Gerontol. 142, 111106 (2020).
Nguyen, C. P. et al. Testosterone and “age-related hypogonadism” — FDA considerations. N. Engl. J. Med. 373, 689–691 (2015).
Hu, Y., Wan, P., An, X. & Jiang, G. Impression of dehydroepiandrosterone (DHEA) supplementation on testosterone concentrations and BMI in aged girls: a meta-analysis of randomized managed trials. Complement. Ther. Med. 56, 102620 (2021).
Nair, Okay. S. et al. DHEA in aged girls and DHEA or testosterone in aged males. N. Engl. J. Med. 355, 1647–1659 (2006).
Kenny, A. M. et al. Dehydroepiandrosterone mixed with train improves muscle energy and bodily operate in frail older girls. J. Am. Geriatr. Soc. 58, 1707–1714 (2010).
Javed, A. A., Mayhew, A. J., Shea, A. Okay. & Raina, P. Affiliation between hormone remedy and muscle mass in postmenopausal girls: a scientific overview and meta-analysis. JAMA Netw. Open 2, e1910154 (2019).
Greising, S. M., Baltgalvis, Okay. A., Lowe, D. A. & Warren, G. L. Hormone remedy and skeletal muscle energy: a meta-analysis. J. Gerontol. A 64, 1071–1081 (2009).
Handlon, A. L. et al. Optimizing ligand effectivity of selective androgen receptor modulators (SARMs). ACS Med. Chem. Lett. 7, 83–88 (2016).
Dalton, J. T. et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean physique mass and bodily operate in wholesome aged males and postmenopausal girls: outcomes of a double-blind, placebo-controlled section II trial. J. Cachexia Sarcopenia Muscle 2, 153–161 (2011).
Papanicolaou, D. A. et al. A section IIA randomized, placebo-controlled scientific trial to check the efficacy and security of the selective androgen receptor modulator (SARM), MK-0773 in feminine contributors with sarcopenia. J. Nutr. Well being Growing older 17, 533–543 (2013).
Fonseca, G. W. P. D., Dworatzek, E., Ebner, N. & Von Haehling, S. Selective androgen receptor modulators (SARMs) as pharmacological remedy for muscle losing in ongoing scientific trials. Skilled Opin. Investig. Medicine 29, 881–891 (2020).
Furrer, R. & Handschin, C. Muscle losing ailments: novel targets and coverings. Annu. Rev. Pharmacol. Toxicol. 59, 315–339 (2019).
Jatoi, A. et al. A placebo-controlled double blind trial of etanercept for the most cancers anorexia/weight reduction syndrome: outcomes from N00C1 from the North Central Most cancers Remedy Group. Most cancers 110, 1396–1403 (2007).
Johnston, A. J. et al. Concentrating on of Fn14 prevents cancer-induced cachexia and prolongs survival. Cell 162, 1365–1378 (2015).
Shrager, J. B. et al. JAK inhibition with tofacitinib quickly will increase contractile pressure in human skeletal muscle. Life Sci. Alliance 7, e202402885 (2024).
Cao, Y., Langer, R. & Ferrara, N. Concentrating on angiogenesis in oncology, ophthalmology and past. Nat. Rev. Drug Discov. 22, 476–495 (2023).
Zhao, G. et al. The soluble VEGF receptor sFlt-1 contributes to impaired neovascularization in aged mice. Growing older Dis. 8, 287–300 (2017).
Grunewald, M. et al. Counteracting age-related VEGF signaling insufficiency promotes wholesome ageing and extends life span. Science 373, eabc8479 (2021).
Serova, M. et al. BIO101 stimulates myoblast differentiation and improves muscle operate in grownup and previous mice. J. Cachexia Sarcopenia Muscle 15, 55–66 (2023).
Burks, T. N. et al. Losartan restores skeletal muscle transforming and protects in opposition to disuse atrophy in sarcopenia. Sci. Transl. Med. 3, 82ra37 (2011).
Heisterberg, M. F. et al. Impact of losartan on the acute response of human aged skeletal muscle to train. Med. Sci. Sports activities Exerc. 50, 225–235 (2018).
Onder, G. et al. Relation between use of angiotensin-converting enzyme inhibitors and muscle energy and bodily operate in older girls: an observational examine. Lancet 359, 926–930 (2002).
Vinel, C. et al. The exerkine apelin reverses age-associated sarcopenia. Nat. Med. 24, 1360–1371 (2018).
Le Moal, E. et al. Apelin stimulation of the vascular skeletal muscle stem cell area of interest enhances endogenous restore in dystrophic mice. Sci. Transl. Med. 16, eabn8529 (2024).
Telesca, M. et al. Results of sacubitril-valsartan on aging-related cardiac dysfunction. Eur. J. Pharmacol. 978, 176794 (2024).
Goodell, M. A. & Rando, T. A. Stem cells and wholesome ageing. Science 350, 1199–1204 (2015).
Mashinchian, O., Pisconti, A., Le Moal, E. & Bentzinger, C. F. The muscle stem cell area of interest in well being and illness. Curr. Prime. Dev. Biol. 126, 23–65 (2018).
Conboy, I. M. et al. Rejuvenation of aged progenitor cells by publicity to a younger systemic atmosphere. Nature 433, 760–764 (2005).
Satellos. Satellos proclaims new knowledge additional demonstrating security, tolerability, and purposeful affect of SAT-3247 in first-in-human trial of adults with Duchenne muscular dystrophy. https://ir.satellos.com/news/news-details/2025/Satellos-Announces-New-Data-Further-Demonstrating-Safety-Tolerability-and-Functional-Impact-of-SAT-3247-in-First-in-Human-Trial-of-Adults-with-Duchenne-Muscular-Dystrophy/default.aspx (2025).
Bernet, J. D. et al. p38 MAPK signaling underlies a cell-autonomous lack of stem cell self-renewal in skeletal muscle of aged mice. Nat. Med. 20, 265–271 (2014).
Value, F. D. et al. Inhibition of JAK-STAT signaling stimulates grownup satellite tv for pc cell operate. Nat. Med. 20, 1174–1181 (2014).
Sampath, S. C. et al. Induction of muscle stem cell quiescence by the secreted area of interest issue Oncostatin M. Nat. Commun. 9, 1531 (2018).
Nalbandian, M. et al. 15-PGDH inhibition promotes muscle restore and energy restoration throughout GLP-1 receptor agonist-induced weight reduction. Proc. Natl Acad. Sci. USA 123, e2606533123 (2026).
Ancel, S. et al. Nicotinamide and pyridoxine stimulate muscle stem cell enlargement and improve regenerative capability throughout ageing. J. Clin. Make investments. 134, e163648 (2024).
Shafiee, G. et al. Bushehr Aged Well being (BEH) programme: examine protocol and design of musculoskeletal system and cognitive operate (stage II). BMJ Open 7, e013606 (2017).
Højfeldt, G. et al. Nicotinamide and pyridoxine supplementation stimulates muscle stem cells in a randomized scientific trial on muscle restore. Preprint at medRxiv https://doi.org/10.1101/2025.03.24.25323226 (2025).
Cruz-Jentoft, A. J. & Sayer, A. A. Sarcopenia. Lancet 393, 2636–2646 (2019).
Pacifico, J. et al. Prevalence of sarcopenia as a comorbid illness: a scientific overview and meta-analysis. Exp. Gerontol. 131, 110801 (2020).
Morley, J. E., Malmstrom, T. Okay., Rodriguez-Mañas, L. & Sinclair, A. J. Frailty, sarcopenia and diabetes. J. Am. Med. Dir. Assoc. 15, 853–859 (2014).
Bowen, T. S., Schuler, G. & Adams, V. Skeletal muscle losing in cachexia and sarcopenia: molecular pathophysiology and affect of train coaching. J. Cachexia Sarcopenia Muscle 6, 197–207 (2015).
Bennett, J. L., Pratt, A. G., Dodds, R., Sayer, A. A. & Isaacs, J. D. Rheumatoid sarcopenia: lack of skeletal muscle energy and mass in rheumatoid arthritis. Nat. Rev. Rheumatol. 19, 239–251 (2023).
Pereira, R. A. et al. Sarcopenia in continual kidney illness on conservative remedy: prevalence and affiliation with mortality. Nephrol. Dial. Transplant. 30, 1718–1725 (2015).
Cruz-Jentoft, A. J. et al. Sarcopenia: European consensus on definition and analysis. Age Ageing 39, 412–423 (2010).
Fielding, R. A. et al. Sarcopenia: an undiagnosed situation in older adults. Present consensus definition: prevalence, etiology, and penalties. Worldwide Working Group on Sarcopenia. J. Am. Med. Dir. Assoc. 12, 249–256 (2011).
Chen, L.-Okay. et al. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. J. Am. Med. Dir. Assoc. 15, 95–101 (2014).
Chen, L.-Okay. et al. Asian Working Group for Sarcopenia: 2019 consensus replace on sarcopenia analysis and remedy. J. Am. Med. Dir. Assoc. 21, 300–307.e2 (2020).
Studenski, S. A. et al. The FNIH Sarcopenia Undertaking: rationale, examine description, convention suggestions, and last estimates. J. Gerontol. A 69, 547–558 (2014).
Albano, D., Messina, C., Vitale, J. & Sconfienza, L. M. Imaging of sarcopenia: previous proof and new insights. Eur. Radiol. 30, 2199–2208 (2020).
Pus, Okay., Sarto, F., Narici, M. & Šimunič, B. The applying of ultrasound sarcopenia index in sarcopenic inhabitants. Exp. Gerontol. 217, 113109 (2026).
Colleluori, G. et al. Cardio plus resistance train in overweight older adults improves muscle protein synthesis and preserves myocellular high quality regardless of weight reduction. Cell Metab. 30, 261–273.e6 (2019).
Kusminski, C. M. et al. Reworking weight problems: the development of multi-receptor medication. Cell 187, 3829–3853 (2024).
Klepac-Bartl, Okay. et al. Amino acids plasma ranges don’t correlate with lean mass loss in weight-matched DIO mice handled with survodutide or semaglutide. Diabetes 73, 2057-LB (2024).
Jeromson, S. et al. Semaglutide impacts skeletal muscle to an identical extent as caloric restriction in mice with diet-induced weight problems. J. Physiol. https://doi.org/10.1113/JP289449 (2025).
Sargeant, J. A. et al. A overview of the consequences of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors on lean physique mass in people. Endocrinol. Metab. 34, 247–262 (2019).
Scheen, A. J. GLP-1-derived therapies and sarcopenia: plea for a selected deal with in danger particular populations. Diabetes Metab. 52, 101708 (2025).
Wang, Y. et al. The apelin receptor agonist azelaprag will increase weight reduction in diet-induced overweight mice on incretin agonists and restores physique composition and muscle operate to that of lean controls. Diabetes 73, 118-OR (2024).
BioAge Labs. BioAge Labs proclaims discontinuation of STRIDES section 2 scientific trial evaluating azelaprag together with tirzepatide for the remedy of weight problems. https://ir.bioagelabs.com/news-releases/news-release-details/bioage-labs-announces-discontinuation-strides-phase-2-clinical/ (2024).
Nunn, E. et al. Antibody blockade of activin sort II receptors preserves skeletal muscle mass and enhances fats loss throughout GLP-1 receptor agonism. Mol. Metab. 80, 101880 (2024).
American Diabetes Affiliation. New GLP-1 therapies improve high quality of weight reduction by enhancing muscle preservation. https://diabetes.org/newsroom/press-releases/new-glp-1-therapies-enhance-quality-weight-loss-improving-muscle-0 (2025).
Mastaitis, J. W. et al. GDF8 and activin a blockade protects in opposition to GLP-1-induced muscle loss whereas enhancing fats loss in overweight male mice and non-human primates. Nat. Commun. 16, 4377 (2025).
Regeneron Prescription drugs Inc. Interim outcomes from ongoing section 2 COURAGE trial verify potential to enhance the standard of semaglutide (GLP-1 receptor agonist)-induced weight reduction by preserving lean mass. https://newsroom.regeneron.com/news-releases/news-release-details/interim-results-ongoing-phase-2-courage-trial-confirm-potential/ (2025).
Moqri, M. et al. Biomarkers of ageing for the identification and analysis of longevity interventions. Cell 186, 3758–3775 (2023).
Horvath, S. & Raj, Okay. DNA methylation-based biomarkers and the epigenetic clock idea of ageing. Nat. Rev. Genet. 19, 371–384 (2018).
Horvath, S. DNA methylation age of human tissues and cell sorts. Genome Biol. 14, R115 (2013).
Petkovich, D. A. et al. Utilizing DNA methylation profiling to judge organic age and longevity interventions. Cell Metab. 25, 954–960.e6 (2017).
Zhang, B. et al. Multi-omic rejuvenation and life span extension on publicity to youthful circulation. Nat. Growing older 3, 948–964 (2023).
Fuentealba, M. et al. A blood-based epigenetic clock for intrinsic capability predicts mortality and is related to scientific, immunological and life-style components. Nat. Growing older 5, 1207–1216 (2025).
Bischoff-Ferrari, H. A. et al. Particular person and additive results of vitamin D, omega-3 and train on DNA methylation clocks of organic ageing in older adults from the DO-HEALTH trial. Nat. Growing older 5, 376–385 (2025).
